Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VCEL on the Frankfort
https://sg.finance.yahoo.com/quote/ATQP.F/community/
BTW, let's find that dialogue that this person is talking about in the first comment listed by ginger, posted 2 days ago YMB
Just a reminder to the shorts trashing ixcell. Recently when Gottlieb (head of the FDA) was giving a speech about exciting new treatments he mentioned ixcell and VCEL's ability to grow heart muscle so when the right partner is found we will benefit IMMENSLY! Best to cover!
VCEL
Yes, and nice on the 4 answers, might get very exciting soon here in VCEL land. I think the 3 analyst st ER/CC were gagged on Ixcell questions, so maybe in between now and the PJ webcast VCEL will light up the PR engine on all 8 cylinders.
Do you have any thoughts as to why we are going to Piper Jaffary and do you think VCEL will pop some cools news prior to webcast?
The phase2b study on the site says it ends November 2018, but
the 10-Q states
"We successfully treated the last patients in February, 2017, and the last follow-up visit will occur approximately one year later. In addition, we have conducted clinical studies for the treatment of critical limb ischemia, and an ixmyelocel-T investigator-initiated clinical study was conducted for the treatment of craniofacial reconstruction. "
The 10-Q mentions Ixcell craniofacial study, but the results were never published, is that right?
Maybe we get something on that soon.
Why is Nick going to Piper Jaffray ? I would wonder if he is going to release partnership news on Ixcell prior to conference?
VCEL : Vericel Corporation Stock Analysis and Research Report dated 10-19-2017
https://fintel.io/b/17458-vcel-vericel-corporation-stock-research-report
Haven't read the user comments yet in it.
Thanks lasers, we know its all coming together, and VCEL has confidentialty agreements, and when they are ready to release, it's going to go viral
And possible crossover study updates, sure they know, Are you excited on this up and coming event ?
I agree, but that $6 is an old P.T. whoa, I am excited. If VCEL discloses Ixcell elements from here to there, could be really exciting.
And possible crossover study updates, sure they know.
lasers, piper jaffery 11-29-2017, what do you think ?
But they will post it on 11-28-2017 as an archive date, per that link I posted
Archive date 11-28-2017, is this when the MACI award gets posted?
http://fbodaily.com/archive/2017/11-November/05-Nov-2017/FBO-04731496.htm
New job position on careers site, weekend requirement
http://vcel.com/careers/
Special Working Conditions:
•Ability to lift 40 lbs.
•Requires working one day per weekend.
•Rotating holiday coverage.
VCEL
The 09-30-2017 balance sheet show A/R was $15.4M, and of that they already collected $4M prior to CC, leaving $11M left to collect on.
http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=12363629&RcvdDate=11/7/2017&CoName=VERICEL%20CORP&FormType=10-Q&View=html
vcel
Read what is in bold below
https://pharmaphorum.com/news/china-accept-overseas-clinical-trial-data/
China to accept overseas clinical trial data
October 9, 2017
The Chinese government has announced plans to accept data from clinical trials carried out overseas, in order to speed up approvals.
Reuters reported that the move was announced by the Chinese cabinet late on Sunday. It is a development that will be welcomed by international pharma companies, as medicines’ approvals are frequently held up because of stringent clinical trial data requirements.
Firms looking to launch drugs in China also face competition from the country’s homegrown pharma companies, and a tough government-controlled pricing environment.
The draft proposals state that the clinical trial data from overseas centres can be used for filings with its CFDA regulator as long as trial centres comply with Chinese drug and medical device registration requirements.
Firms looking to register drugs or medical devices for the first time will need to provide clinical trial data related to genetic differences in the Chinese population.
China is trying to shift away from use of generics and towards more innovative medicines and medical equipment.
The country’s State Council added the changes would make the country’s industry more competitive and help meet the clinical needs of its nearly 1.4 billion people.
China is becoming increasingly important to pharma companies because of the size of its population, prevalence of certain diseases, and its developing healthcare sector.
Cancer biotech BeyondSpring hopes to do the bulk of R&D for its new lung cancer drug plinabulin in China, a strategy that will cut development costs because of its links with hospitals and regulators.
Other companies have used similar strategies – Boehringer Ingelheim’s lung cancer drug Giotrif was approved by the FDA in trials where 72% of patients in a pivotal phase 3 trial were from China.
International pharma are also interested in developing diabetes drugs in China – AstraZeneca and Novo Nordisk are among the companies that are targeting the market, where around 150 million people are predicted to develop type 2 diabetes by 2040.
Novo Nordisk is hoping to gain a foothold with GLP-1 class diabetes drugs such as Victoza (liraglutide) and its developmental successor semaglutide.
And AstraZeneca late last month said it plans filings of its Bevespi Aerosphere COPD drug in China, where older drugs such as salmeterol and formoterol are commonly used to manage COPD symptoms.
Something is going on, the Tute ownership is increasing and the company is ever so hush hush
Wonder if one day VCEL and ICT will be connected at the hip?
http://www.ictbio.com/page51.html
VCEL
Do you think ICT will eventually play a bigger role in VCEL than what we are led to believe?
https://www.nytimes.com/reuters/2017/11/06/business/06reuters-goldman-sachs-cic.html
VCEL
VCEL 13-F filed yesterday
https://fintel.io/sob/us/vcel
Add to the cash the $4M already collected from A/R after 09-30-2017 and the coming $5.5M ICT down payment, so nearly $25M cash on hand this quarter,
PRETTY STRONG CASH BASE, wouldn't you think lasers
Did you see the new 13-F filed today, another $1B tute invested $1M
VCEL
lasers, you are saying they are going to stack a deferred $9.5M 3rd quarter revenue onto the 4th quarter 10KSB to have revenues of nearly $25 million revenue for the 4th quarter ?
lasers,
regarding the US Army Contract proprosal coming November 14th, or so
https://www.fbo.gov/index?s=opportunity&mode=form&id=fb98abca15177138d1ac00cea8eca461&tab=core&_cview=0
https://www.google.com/search?source=hp&ei=RVQCWsLHL4TCjwTKsKnYDg&q=AmerisourceBergen&oq=AmerisourceBergen&gs_l=psy-ab.3..0i131k1l2j0l8.1839.1839.0.3299.1.1.0.0.0.0.190.190.0j1.1.0....0...1.1.64.psy-ab..0.1.189....0.wupDZHQ4k-A
AmerisourceBergen
Wholesale company
amerisourcebergen.com
AmerisourceBergen Corporation is an American drug wholesale company that was formed by the merger of Bergen Brunswig and AmeriSource in 2001. Wikipedia
Stock price: ABC (NYSE) $74.91 +0.07 (+0.09%)
Nov 7, 4:01 PM EST - Disclaimer
Headquarters: Chesterbrook, Tredyffrin Township, PA
CEO: Steven H Collis (Jul 1, 2011–)
Revenue: 135.9 billion USD (2015)
Number of employees: 16,500 (2015)
Founded: 2001
Subsidiaries: AmerisourceBergen Specialty Group, MORE
VCEL
I see where you got the 4.90 from, but is that from an amended contract, and what is the date of that contract, is the contract in the 10-Q, let me look again
http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=12363629&RcvdDate=11/7/2017&CoName=VERICEL%20CORP&FormType=10-Q&View=html
License Agreement
On May 10, 2017, the Company announced that it has entered into a License Agreement (License Agreement) with Innovative Cellular Therapeutics Co. Ltd, (ICT), a leading cell therapy company and developer of CAR-T cell therapy for cancer treatment,
13
for the development and distribution of the Vericel product portfolio in Greater China, South Korea, Singapore, and other countries in Asia. ICT will acquire an exclusive license to certain patent rights, know-how and intellectual property relating to Carticel, MACI, ixmyelocel-T, and Epicel as well as enter into a warrant purchase agreement. As part of the license and warrant purchase agreements, the Company will receive an upfront payment of $6.0 million , less any applicable taxes, within 60 days of the effective date of the License Agreement. The initiation of the technology transfer, the license grants in the License Agreement and the warrant purchase are contingent upon Vericel’s receipt of the upfront payment. Vericel is eligible to receive approximately $8.0 million in development and commercial milestones. ICT has also agreed to pay tiered royalties to Vericel equal to a percentage of net sales of each Licensed Product in the low double digits for the commercial life of the applicable Licensed Product. ICT will be responsible for funding the development of the programs and manufacturing of the products for commercialization in China and the rest of the territory. The funding transfer is subject to approval by the State Administration of Foreign Exchange of the People's Republic of China and has not occurred as of issuance date of the financial statements. As a result, the parties have amended the agreement monthly to provide additional time for ICT to pay and reset certain terms of the warrant. The initiation of the technology transfer, the license grants in the License Agreement and the warrant purchase have not occurred. As partial consideration for an amount included in the upfront payment Vericel will issue to ICT a warrant, exercisable for the number of shares of Vericel’s Common Stock equal to $5.0 million less the withholding tax payable thereon divided by $4.90 currently (formerly $3.05 ), with a strike price of $0.01 per share.
14
VCEL
There is no doubt that VCEL is in great money shape.
The conference call today stated "this quarter", at least VCEL bumped the pps to 4.30 from originally 2.55
Just noticed in the 10-Q the Amended ICT contract has changed from 2.55 to 4.30
http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=12363629&RcvdDate=11/7/2017&CoName=VERICEL%20CORP&FormType=10-Q&View=html
EXHIBIT 10.7
CONFIDENTIAL
AMENDMENT NO. 2 TO LETTER AGREEMENT
This Amendment No 2 (“ Amendment 2 ”) to the Letter Agreement (as defined below) dated as of September 5, 2017 (the “ Amendment Date ”), is entered into by and between “???????ï??????” (Innovative Cellular Therapeutics CO., LTD.), a corporation organized and existing under the laws of China (“ ICT ”), and Vericel Corporation, a corporation organized and existing under the laws of the State of Michigan (“ Vericel ”). Terms used, but not defined, herein shall have the meaning ascribed to them in the Letter Agreement. ICT and Vericel are each referred to herein as a “ Party ” or collectively the “ Parties ”.
RECITALS
WHEREAS , Vericel and ICT are parties to that certain License Agreement, dated as of May 9, 2017 (the “ License Agreement ”); and
WHEREAS , in connection with entering into the License Agreement, Vericel and ICT entered into that certain letter agreement, dated as of May 9, 2017 (the “ Letter Agreement ”); and
WHEREAS , the Parties desire to amend the Letter Agreement on the terms and subject to the conditions set forth herein, with this Amendment 2 becoming effective on September 6, 2017 at 4:00 pm Eastern Daylight Time (the “ Effective Time ”) if the Upfront Payment (as defined in the License Agreement) is not received by Vericel from ICT at or before the Effective Time (the “ Nonpayment Condition ”).
NOW, THEREFORE , in consideration of the foregoing premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:
1.
AMENDMENTS
1.1 The third (3 rd ) sentence of the second (2 nd ) full paragraph of the Letter Agreement is hereby deleted in its entirety and replaced with the following:
As consideration for an amount included in the Upfront Payment equal to (a) $5,000,000.00 minus (b) the Withholding Income Taxes (such amount, the “ Warrant Purchase Price ”), Vericel hereby agrees to issue to ICT, effective as of and contingent upon Vericel's receipt of the Upfront Payment, a warrant (the “ Common Stock Warrant ”) in substantially the form attached hereto as Exhibit A , exercisable for the number of shares of Vericel's Common Stock equal to (x) the Warrant Purchase Price divided by (y) $4.30 the closing price of a share of Vericel's Common Stock on the Nasdaq Stock Market on September 5, 2017, rounded down to the nearest whole number.
1.2 The third (3 rd ) full paragraph of the Letter Agreement is hereby deleted in its entirety and replaced with the following:
If ICT fails to pay the Upfront Payment to Vericel pursuant to the terms of the License Agreement by October 6, 2017, Vericel's obligation to issue the Common Stock Warrant to ICT pursuant to the terms hereof shall terminate in its entirety and shall be of no further force or effect.
2. MISCELLANEOUS
2.1 This Amendment 2 shall become effective at the Effective Time if, and only if, the Nonpayment Condition has occurred.
2.2. Except to the extent modified herein, the terms and conditions of the Letter Agreement shall remain in full force and effect.
2.3 This Amendment 2 shall be governed by and construed in accordance with the laws of the State of New York, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Amendment to the substantive law of another jurisdiction.
2.4 This Amendment 2 may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Electronic copies or facsimiles of signatures shall be deemed originals.
* * * * *
IN WITNESS WHEREOF, the Parties have executed this Amendment No. 2 to the Letter Agreement as of the Amendment Date.
Innovative Cellular Therapeutics Co., Ltd.
Vericel Corporation
BY:___/s/Lei Xiao_____________________
NAME: __Lei Xiao____________________
TITLE: __Chairman___________________
BY:____/s/Dominick Colangelo__________
NAME: __Dominick Colangelo__________
TITLE: __Chief Executive Officer________
ICT contracts in the 10Q
lasers, why no mention of Ixcell in the CC ?
Wonder if Nick is going to comment on ixcel partnership or ICT?
You nailed it, 2018 going to be a great growth year
heck, R&D expenses on the Ixmyelocel-T crossover study should be winding down hugely, with results coming in Feb 2018
So I still expect tomorrow positive ER
I don't think ER will come in at less than -.03, but what I bet all radars are on will be Ixmyelocel-T and where's the beef
"the partner" and also what is going on with ICT ?
Personally, I am expecting positive earnings, but we will see in hours and a wakeup.
Should get news at 7am, would like to see 25 million total revenues, or better
20mil MACI
5 mil Epicel
Award will be made on or about 14 November 2017. The NAICS code 339113, size standard is 750.
750 MACI???, is that what this means???, then this means a $32M contract
https://govtribe.com/project/maci-autologous-tissue-graft/activity
VCEL
CCI, Interesting this article states MACI has been around since 1986
Vermillion was able to learn an early version of the MACI procedure, this one developed in 1986 by Swedish medical doctor Lars Peterson of the International Cartilage Repair Society. He developed procedure that involved growing patients’ own cartilage cells in test tubes.
Thinking VCEL will give us positive .02 to .05 per share this quarter, what do you think?
http://www.nasdaq.com/earnings/report/vcel
VCEL
Another job opening requiring weekends and holidays for VCEL
http://vcel.com/careers/?req=641436
Special Working Conditions:
•Ability to lift 40 lbs.
•Requires working one day per weekend.
•Rotating holiday coverage.
VCEL
Absolutely no reason pps should be under $5, tomorrow we get the short numbers after the bell
How long does it take for a partnership deal to get inked ?
Suppose the first thing signed by both parties are confidentiality agreements, wouldn't you think ?
So, if a partner is to be announced, its anyones guess as to when, except that the ER/CC is fastly approaching in 2 to 3 weeks.
I would think the analyst's will be probing questions on CC
lasers, I see the 50dma bumped up to $4.50, and Guess the clock is ticking from now to ER/CC for the release of partnership news.
We will have an answer in about 3 weeks if VCEL makes history on being the first profitable stem cell company in the USA
One year from now I am hoping VCEL gains to $15-18 pps